STU:0O2 (USA)
Â
Ordinary Shares - Series A
€
6.14
+0.10 (+1.66%)
Jun 26
Business Description
Sagimet Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US7867001049
Share Class Description:
STU:0O2: Ordinary Shares - Series ATotal Employee Number:
16Description
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2680.49 | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.9 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | -8.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.84 | |||||
9-Day RSI | 60.95 | |||||
14-Day RSI | 56.72 | |||||
3-1 Month Momentum % | 40.45 | |||||
6-1 Month Momentum % | 17.71 | |||||
12-1 Month Momentum % | -15.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.34 | |||||
Quick Ratio | 20.34 | |||||
Cash Ratio | 19.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -36.12 | |||||
ROA % | -34.2 | |||||
ROIC % | -1228.31 | |||||
3-Year ROIIC % | 10501.63 | |||||
ROC (Joel Greenblatt) % | -57745.26 | |||||
ROCE % | -40.46 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.25 | |||||
Price-to-Tangible-Book | 2.25 | |||||
EV-to-EBIT | -6.8 | |||||
EV-to-EBITDA | -6.8 | |||||
EV-to-Forward-Revenue | 26.15 | |||||
EV-to-FCF | -8.34 | |||||
| Price-to-Net-Current-Asset-Value | 2.25 | |||||
| Price-to-Net-Cash | 2.32 | |||||
Earnings Yield (Greenblatt) % | -14.71 | |||||
FCF Yield % | -9.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sagimet Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.151 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 133.25 | ||
| 14-Day RSI | 56.72 | ||
| 14-Day ATR (€) | 0.263553 | ||
| 20-Day SMA (€) | 5.814 | ||
| 12-1 Month Momentum % | -15.34 | ||
| 52-Week Range (€) | 3.92 - 8.7 | ||
| Shares Outstanding (Mil) | 61.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sagimet Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sagimet Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 45 days | ||
| General meeting for 2026 | 2026-06-12 09:30 | 5.50 (-1.08%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 14:00 | 5.68 (-2.07%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 6.50 (+0.93%) | ||
| Sagimet Biosciences Virtual KOL Event | 2026-04-30 14:00 | 7.24 (-1.90%) | ||
| Annual report for 2025 | 2026-03-11 | 4.68 (+2.18%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 4.68 (+2.18%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 10:45 | 4.62 (+0.87%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 13:00 | 4.64 (+0.43%) |
Show
Entries
Sagimet Biosciences Inc Frequently Asked Questions
What is Sagimet Biosciences Inc(STU:0O2)'s stock price today?
The current price of STU:0O2 is €6.14. The 52 week high of STU:0O2 is €8.70 and 52 week low is €3.92.
When is next earnings date of Sagimet Biosciences Inc(STU:0O2)?
The next earnings date of Sagimet Biosciences Inc(STU:0O2) is 2026-08-13 Est..
Does Sagimet Biosciences Inc(STU:0O2) pay dividends? If so, how much?
Sagimet Biosciences Inc(STU:0O2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sagimet Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers